308846-06-2

Basic information

• Product Name: 2-Cyano-5-bromomethylpyridine
• Synonyms: 5-(BROMOMETHYL)PYRIDINE-2-CARBONITRILE;5-(bromomethyl)picolinonitrile;2-Cyano-5-bromomethylpyridine;5-(Bromomethyl)-2-cyanopyridine, 5-(Bromomethyl)picolinonitrile;2-cyano-5-broMide-Methyl pyridine;5-(broMoMethyl)-2-pyridinecarbonitrile;2-Pyridinecarbonitrile, 5-(broMoMethyl)-
• CAS NO: 308846-06-2
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• Product Categories: Methyl Halides;Pyridines;Methyl Halides
• Mol File: 308846-06-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 329.5 ºC at 760 mmHg
• Flash Point: 153.1 ºC
• Appearance: /
• Density: 1.607 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.23±0.10(Predicted)
• CAS DataBase Reference: 2-Cyano-5-bromomethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyano-5-bromomethylpyridine(308846-06-2)
• EPA Substance Registry System: 2-Cyano-5-bromomethylpyridine(308846-06-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 308846-06-2(Hazardous Substances Data)

Usage

General Description

2-Cyano-5-bromomethylpyridine is a chemical compound with the molecular formula C7H5BrN2. It is a pyridine derivative with a cyano group at the 2-position and a bromomethyl group at the 5-position. 2-Cyano-5-bromomethylpyridine is used in organic synthesis as a building block for the preparation of various pharmaceutical and agrochemical products. It is also used as an intermediate in the production of active ingredients for the pharmaceutical industry. Additionally, 2-Cyano-5-bromomethylpyridine is utilized in the field of materials science for the synthesis of polymers and other advanced materials. Due to its unique structure and versatile applications, this chemical compound is of interest to researchers and scientists in various fields.

InChI:InChI=1/C7H5BrN2/c8-3-6-1-2-7(4-9)10-5-6/h1-2,5H,3H2

Upstream product

• 1620-77-5 5-methylpicolinonitrile 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 94-36-0 dibenzoyl peroxide 
• 128-08-5 N-Bromosuccinimide 

Downstream Products

• 1027428-59-6 (S)-1-((R)-2-Amino-3,3-diphenyl-propionyl)-pyrrolidine-2-carboxylic acid (6-cyano-pyridin-3-ylmethyl)-amide 
• 181130-14-3 5-(aminomethyl)pyridine-2-carbonitrile 
• 1268245-86-8 C₂₀H₂₃ClN₂OSi 
• 1268245-14-2 4-((4-(2-(6-(1H-tetrazol-5-yl)pyridin-3-yl)cyclopropyl)-3-chlorophenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1268245-15-3 5-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)picolinic acid 
• 1372174-98-5 (S)-4-chloro-N-((6-cyanopyridin-3-yl)methyl)-N-(1-phenylpropyl)benzenesulfonamide 
• 1372174-96-3 N-((6-cyanopyridin-3-yl)methyl)-4-chloro-N-(pentan-3-yl)benzenesulfonamide 

Relevant articles and documents

Development of18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging

Pretargeted PET imaging is an emerging and fast-developing method to monitor immunooncology strategies. Currently, tetrazine ligation is considered the most promising bioorthogonal reaction for pretargeting in vivo. Recently, we have developed a method to18F-label ultrareactive tetrazines by copper-mediated fluorinations. However, bispyridyl tetrazines—one of the most promising structures for in vivo pretargeted applications—were inaccessible using this strategy. We believed that our successful efforts to18F-label H-tetrazines using low basic labeling conditions could also be used to label bispyridyl tetrazines via aliphatic nucleophilic substitution. Here, we report the first direct18F-labeling of bispyridyl tetrazines, their optimization for in vivo use, as well as their successful application in pretargeted PET imaging. This strategy resulted in the design of [18F]45, which could be labeled in a satisfactorily radiochemical yield (RCY = 16%), molar activity (Am = 57 GBq/μmol), and high radiochemical purity (RCP > 98%). The [18F]45 displayed a target-to-background ratio comparable to previously successfully applied tracers for pretargeted imaging. This study showed that bispyridyl tetrazines can be developed into pretargeted imaging agents. These structures allow an easy chemical modification of18F-labeled tetrazines, paving the road toward highly functionalized pretargeting tools. Moreover, bispyridyl tetrazines led to near-instant drug release of iTCO-tetrazine-based ‘click-to-release’ reactions. Consequently,18F-labeled bispyridyl tetrazines bear the possibility to quantify such release in vivo in the future.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.